These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
529 related articles for article (PubMed ID: 28448999)
1. Outcome of All-Oral Direct-Acting Antiviral Regimens on the Rate of Development of Hepatocellular Carcinoma in Patients with Hepatitis C Virus Genotype 1-Related Chronic Liver Disease. Ogata F; Kobayashi M; Akuta N; Osawa M; Fujiyama S; Kawamura Y; Sezaki H; Hosaka T; Kobayashi M; Saitoh S; Suzuki Y; Suzuki F; Arase Y; Ikeda K; Kumada H Oncology; 2017; 93(2):92-98. PubMed ID: 28448999 [TBL] [Abstract][Full Text] [Related]
2. Liver Fibrosis and Body Mass Index Predict Hepatocarcinogenesis following Eradication of Hepatitis C Virus RNA by Direct-Acting Antivirals. Akuta N; Kobayashi M; Suzuki F; Sezaki H; Fujiyama S; Kawamura Y; Hosaka T; Kobayashi M; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kumada H Oncology; 2016; 91(6):341-347. PubMed ID: 27694754 [TBL] [Abstract][Full Text] [Related]
3. Complex Association of Virus- and Host-Related Factors with Hepatocellular Carcinoma Rate following Hepatitis C Virus Clearance. Akuta N; Suzuki F; Sezaki H; Kobayashi M; Fujiyama S; Kawamura Y; Hosaka T; Kobayashi M; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kumada H J Clin Microbiol; 2019 Jan; 57(1):. PubMed ID: 30381417 [TBL] [Abstract][Full Text] [Related]
4. Impact of Hepatitis C Virus Eradication on the Clinical Outcome of Patients with Hepatitis C Virus-Related Advanced Hepatocellular Carcinoma Treated with Sorafenib. Kawaoka T; Aikata H; Teraoka Y; Inagaki Y; Honda F; Hatooka M; Morio K; Morio R; Kobayashi T; Nagaoki Y; Nakahara T; Hiramatsu A; Tsuge M; Imamura M; Kawakami Y; Chayama K Oncology; 2017; 92(6):335-346. PubMed ID: 28245484 [TBL] [Abstract][Full Text] [Related]
5. Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients. Hung CH; Lu SN; Wang JH; Hu TH; Chen CH; Huang CM; Lee CM Antivir Ther; 2011; 16(7):959-68. PubMed ID: 22024511 [TBL] [Abstract][Full Text] [Related]
6. High post-treatment absolute monocyte count predicted hepatocellular carcinoma risk in HCV patients who failed peginterferon/ribavirin therapy. Chen TM; Lin CC; Huang PT; Wen CF Tumour Biol; 2016 Jun; 37(6):7129-37. PubMed ID: 26662957 [TBL] [Abstract][Full Text] [Related]
7. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals. Prenner SB; VanWagner LB; Flamm SL; Salem R; Lewandowski RJ; Kulik L J Hepatol; 2017 Jun; 66(6):1173-1181. PubMed ID: 28161470 [TBL] [Abstract][Full Text] [Related]
8. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C. Furusyo N; Ogawa E; Nakamuta M; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Hayashi J; J Hepatol; 2013 Aug; 59(2):205-12. PubMed ID: 23542346 [TBL] [Abstract][Full Text] [Related]
9. Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis. Mettke F; Schlevogt B; Deterding K; Wranke A; Smith A; Port K; Manns MP; Vogel A; Cornberg M; Wedemeyer H Aliment Pharmacol Ther; 2018 Feb; 47(4):516-525. PubMed ID: 29205405 [TBL] [Abstract][Full Text] [Related]
10. Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin. Ng KJ; Tseng CW; Chang TT; Tzeng SJ; Hsieh YH; Hung TH; Huang HT; Wu SF; Tseng KC Clin Interv Aging; 2016; 11():1035-41. PubMed ID: 27536084 [TBL] [Abstract][Full Text] [Related]
11. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy. Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854 [TBL] [Abstract][Full Text] [Related]
12. Does antiviral therapy reduce the risk of hepatocellular carcinoma in patients with chronic hepatitis C? Michielsen P; Ho E; Francque S Minerva Gastroenterol Dietol; 2012 Mar; 58(1):65-79. PubMed ID: 22419005 [TBL] [Abstract][Full Text] [Related]
13. Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy. Akuta N; Suzuki F; Hirakawa M; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H J Med Virol; 2011 Jun; 83(6):1016-22. PubMed ID: 21503914 [TBL] [Abstract][Full Text] [Related]
14. Short-term risk of hepatocellular carcinoma after hepatitis C virus eradication following direct-acting anti-viral treatment. Ogawa E; Furusyo N; Nomura H; Dohmen K; Higashi N; Takahashi K; Kawano A; Azuma K; Satoh T; Nakamuta M; Koyanagi T; Kato M; Shimoda S; Kajiwara E; Hayashi J; Aliment Pharmacol Ther; 2018 Jan; 47(1):104-113. PubMed ID: 29035002 [TBL] [Abstract][Full Text] [Related]
15. Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection. Kobayashi M; Suzuki F; Fujiyama S; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kumada H J Med Virol; 2017 Mar; 89(3):476-483. PubMed ID: 27531586 [TBL] [Abstract][Full Text] [Related]
16. Late development of hepatocellular carcinoma after viral clearance in patients with chronic hepatitis C: A need for continual surveillance. Tong MJ; Theodoro CF; Salvo RT J Dig Dis; 2018 Jul; 19(7):411-420. PubMed ID: 29889353 [TBL] [Abstract][Full Text] [Related]
17. Past history of hepatocellular carcinoma is an independent risk factor of treatment failure in patients with chronic hepatitis C virus infection receiving direct-acting antivirals. Sugiura A; Joshita S; Umemura T; Yamazaki T; Fujimori N; Kimura T; Matsumoto A; Igarashi K; Usami Y; Wada S; Mori H; Shibata S; Yoshizawa K; Morita S; Furuta K; Kamijo A; Iijima A; Kako S; Maruyama A; Kobayashi M; Komatsu M; Matsumura M; Miyabayashi C; Ichijo T; Takeuchi A; Koike Y; Gibo Y; Tsukadaira T; Inada H; Kiyosawa K; Tanaka E J Viral Hepat; 2018 Dec; 25(12):1462-1471. PubMed ID: 30044517 [TBL] [Abstract][Full Text] [Related]
18. Impact of direct-acting antivirals on early recurrence of HCV-related HCC: Comparison with interferon-based therapy. Nishibatake Kinoshita M; Minami T; Tateishi R; Wake T; Nakagomi R; Fujiwara N; Sato M; Uchino K; Enooku K; Nakagawa H; Asaoka Y; Shiina S; Koike K J Hepatol; 2019 Jan; 70(1):78-86. PubMed ID: 30336183 [TBL] [Abstract][Full Text] [Related]
19. Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals. Pons M; Rodríguez-Tajes S; Esteban JI; Mariño Z; Vargas V; Lens S; Buti M; Augustin S; Forns X; Mínguez B; Genescà J J Hepatol; 2020 Mar; 72(3):472-480. PubMed ID: 31629779 [TBL] [Abstract][Full Text] [Related]
20. Pretreatment AKR1B10 expression predicts the risk of hepatocellular carcinoma development after hepatitis C virus eradication. Murata A; Genda T; Ichida T; Amano N; Sato S; Tsuzura H; Sato S; Narita Y; Kanemitsu Y; Shimada Y; Hirano K; Iijima K; Wada R; Nagahara A; Watanabe S World J Gastroenterol; 2016 Sep; 22(33):7569-78. PubMed ID: 27672277 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]